Trial Profile
Open-label, Uncontrolled, Single-arm, Phase Ib/II Study of Intravenous Copanlisib in Japanese Patients With Indolent B-cell Non Hodgkin's Lymphomas Relapsed After or Refractory to Standard Therapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer; Bayer Yakuhin
- 01 Jan 2023 Results reporting toxicity and efficacy data published in the International Journal of Hematology
- 18 Feb 2022 Status changed from active, no longer recruiting to completed.
- 08 Dec 2021 New source identified and integrated Japan Pharmaceutical Information Center - Clinical Trials Information (JapicCTI152801)